

38. (Amended) A composition for effecting therapy of a tumor or an infectious disease in a patient, comprising:

(A) a first conjugate comprising a targeting moiety, a first member of a binding pair, and a first therapeutic agent, wherein the targeting moiety is multivalent and selectively binds to multiple epitopes of a marker substance produced by or associated with the tumor or infectious disease causing agent or binds to multiple marker substances produced by or associated with the tumor or infectious disease causing agent,

(B) optionally, a clearing agent; and

(C) a second conjugate comprising a complementary member of said binding pair and a second therapeutic agent, wherein the second therapeutic agent is the same as or different from the first therapeutic agent,

wherein the binding pair is selected from the group consisting of (a) complementary DNA fragments, (b) complementary peptide oligonucleotides, and (c) corresponding enzymes and prodrug substrates.

Sub C1
51
53. (New) The composition of claim 11, wherein said hormones and antagonists are selected from the group consisting of wherein said hormones and antagonists are selected from the group consisting of adrenocorticosteroids, progestins, estrogens, and androgens.

34
52
54. (New) The composition of claim 14, wherein said hormones and antagonists are selected from the group consisting of adrenocorticosteroids, progestins, estrogens, and androgens.

REMARKS

Introduction

Receipt is acknowledged of the Office Action dated January 11, 2002. In the Action the Examiner has rejected claims 1-42, 44 and 46-52 under the judicially created doctrine of obviousness-type double patenting. The examiner